Claims for Patent: 12,403,120

Summary for Patent: 12,403,120

Title:	Pharmaceutical compositions of furosemide and uses thereof
Abstract:	A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof is disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and tris(hydroxymethyl)aminomethane. The furosemide is present in the pharmaceutical composition at a concentration from about 10 mg/mL to about 30 mg/mL and the tris(hydroxymethyl)aminomethane is present at a concentration of less than or equal to 40 mM. The pH value of the pharmaceutical composition is maintained between about 8.0 and about 8.5 for parenteral administration.
Inventor(s):	Pieter Muntendam
Assignee:	SQ Innovation AG
Application Number:	US17/311,634
Patent Claims:	1. A pharmaceutical composition, comprising: furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof; and tris(hydroxymethyl)aminomethane; wherein the furosemide is present in the pharmaceutical composition at a concentration from about 10 mg/mL to about 30 mg/mL; the tris(hydroxymethyl)aminomethane is present in the pharmaceutical composition at a concentration of less than or equal to 40 mM; and the pharmaceutical composition has a pH value from about 8.0 to about 8.5; wherein the pharmaceutical composition has a molar ratio of the tris(hydroxymethyl)aminomethane to the furosemide of less than or equal to 0.8. 2. The pharmaceutical composition of claim 1, wherein the furosemide is present in the pharmaceutical composition at a concentration from about 25 mg/mL to about 30 mg/mL. 3. The pharmaceutical composition of claim 1, wherein the furosemide is present in the pharmaceutical composition at a concentration of about 30 mg/mL. 4. The pharmaceutical composition of claim 1, wherein the tris(hydroxymethyl)aminomethane is present in the pharmaceutical composition at a concentration of from about 5 mM to about 40 mM. 5. The pharmaceutical composition of claim 1, wherein the tris(hydroxymethyl)aminomethane is present in the pharmaceutical composition at a concentration of less than or equal to about 25 mM. 6. The pharmaceutical composition of claim 3, wherein the tris(hydroxymethyl)aminomethane is present in the pharmaceutical composition at a concentration of from about 20 mM to about 30 mM. 7. The pharmaceutical composition of claim 3, further comprising water. 8. The pharmaceutical composition of claim 4, further comprising water. 9. The pharmaceutical composition of claim 6, further comprising water. 10. The pharmaceutical composition of claim 1, wherein the concentration of the furosemide after storage at 70° C. for 29 days is about 94% of the original furosemide concentration. 11. The pharmaceutical composition of claim 1, wherein the pH of the pharmaceutical composition after storage at 70° C. for 29 days is about 97% of the original pH value. 12. A pharmaceutical composition, comprising: from about 60 mM to about 95 mM of a diuretic wherein the diuretic is 4-chloro-2-((furan-2-ylmethyl)amino)-5-sulfamoylbenzoic acid, or a pharmaceutically acceptable salt thereof, or a mixture of the foregoing; from about 20 mM to about 30 mM of a buffer comprising tris(hydroxymethyl)aminomethane; and water; wherein the pharmaceutical composition has a pH value from about 8.0 to about 8.5. 13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition comprises from about 80 mM to about 95 mM of the diuretic. 14. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition comprises about 91 mM of the diuretic. 15. The pharmaceutical composition of claim 12, wherein the diuretic is a mixture of 4-chloro-2-((furan-2-ylmethyl)amino)-5-sulfamoylbenzoic acid and a pharmaceutically acceptable salt thereof. 16. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises about 25 mM of a buffer comprising tris(hydroxymethyl)aminomethane. 17. The pharmaceutical composition of claim 12, wherein said buffer is a mixture of tris(hydroxymethyl)aminomethane and a pharmaceutically acceptable salt thereof. 18. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition has a pH of from about 8.2 to about 8.5. 19. The pharmaceutical composition of claim 12, wherein less than 4% of the diuretic degrades upon storage of the pharmaceutical composition at 40° C. for 29 days. 20. The pharmaceutical composition of claim 12, wherein less than 1% of the diuretic degrades upon storage of the pharmaceutical composition at 40° C. for 29 days. 21. The pharmaceutical composition of claim 12, wherein less than 10% of the diuretic degrades upon storage of the pharmaceutical composition at 70° C. for 29 days. 22. The pharmaceutical composition of claim 12, wherein less than 7% of the diuretic degrades upon storage of the pharmaceutical composition at 70° C. for 29 days. 23. A method of treating a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof, the method comprising: administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 1. 24. A method of treating a patient suffering from a condition selected from edema, heart failure, kidney disease, or liver disease, or having a symptom any of the foregoing, comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 12 to treat the condition. 25. The method of claim 24, wherein the condition is edema. 26. The method of claim 24, wherein the condition is heart failure.